Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Rushi Parikh, MD (ucla)

Description

Summary

The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH. The study cohort will consist of patients with pulmonary pressures ranging from normal (advanced lung disease patients undergoing lung transplant evaluation) to severe PH (PAH and CTEPH patients), and thus will allow for identification of a PIMR cutoff. Participants will include: 1) advanced lung disease patients undergoing bilateral heart catheterization as part of their pre-lung transplant work-up, and 2) newly referred patients to PAH and CTEPH clinics undergoing bilateral heart catheterization as part of standard of care work-up. All participants will undergo PIMR testing, and those with pre-capillary PH will also undergo pulmonary OCT and measurement of RV-IMR. The study seeks to define the relationship between PIMR and PH and to establish the PIMR threshold that identifies pulmonary microvascular dysfunction as well as to evaluate the association of PIMR and pulmonary vascular remodeling on OCT in patients with pre-capillary PH. In addition, the study will assess the relationship between RV-IMR and RV pressure overload among patients with pre-capillary PH.

Official Title

The Pulmonary Index of Microcirculatory Resistance: A Novel Hemodynamic Index for Invasively Assessing the Pulmonary Vasculature

Keywords

Pulmonary Hypertension, Pulmonary Arterial Hypertension, Index of Microcirculatory Resistance, Chronic Thromboembolic Disease, Pulmonary Index of Microcirculatory Resistance, Hypertension, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT, CTEPH

Eligibility

You can join if…

Open to people ages 18 years and up

  • ≥18 years old
  • Able to provide informed written consent.
  • Patients with 1) advanced lung disease requiring standard-of-care bilateral heart catheterization as part of lung transplant evaluation in whom mPAP < 20 mmHg on RHC, or 2) PAH/CTEPH (i.e. pre-capillary PH) undergoing standard-of-care bilateral heart catheterization as part of their work-up/treatment

You CAN'T join if...

  • Contraindicated to undergo fluoroscopy and/or coronary angiography (e.g. pregnancy)
  • Chronic kidney disease (serum creatinine ≥ 2.0 mg/dL)

Location

  • Ronald Reagan UCLA Medical Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Rushi Parikh, MD (ucla)
    HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 48 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT05843461
Study Type
Observational
Participants
Expecting 30 study participants
Last Updated